Moderna’s first-quarter sales exceed expectations
Moderna’s (NASDAQ: MRNA) first-quarter results surpassed analysts’ expectations after its revenue more than tripled from the year-ago quarter to $6.1 billion due to the sales of its COVID-19 vaccine
By Yashasvini Razdan
Published - May 04, 2022, 04:24 PM ET
Last Updated - Feb 26, 2024, 08:52 AM EST
• The company’s net income for the quarter surged to $3.66 billion
Moderna’s (NASDAQ: MRNA) first-quarter results surpassed analysts’ expectations after its revenue more than tripled from the year-ago quarter to $6.1 billion due to the sales of its COVID-19 vaccine.
The company’s net income for the quarter surged to $3.66 billion, a threefold increase over the $1.2 billion it reported in the same period last year.
Adjusted earnings per share were reported as $8.58 per share, versus the $5.21 per share estimated by analysts.
